| Catalytic enantioselective rearrangements and cycloadditions involving ylides from diazo compounds DM Hodgson, FYTM Pierard, PA Stupple Chemical Society Reviews 30 (1), 50-61, 2001 | 383 | 2001 |
| Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels K McCormack, S Santos, ML Chapman, DS Krafte, BE Marron, CW West, ... Proceedings of the National Academy of Sciences 110 (29), E2724-E2732, 2013 | 234 | 2013 |
| Organocatalytic Asymmetric Total Synthesis of (R)-Rolipram and Formal Synthesis of (3S,4R)-Paroxetine PS Hynes, PA Stupple, DJ Dixon Organic Letters 10 (7), 1389-1391, 2008 | 199 | 2008 |
| Subtype-selective small molecule inhibitors reveal a fundamental role for Nav1. 7 in nociceptor electrogenesis, axonal conduction and presynaptic release AJ Alexandrou, AR Brown, ML Chapman, M Estacion, J Turner, MA Mis, ... PloS one 11 (4), e0152405, 2016 | 173 | 2016 |
| Development of Dirhodium(II)‐Catalyzed Generation and Enantioselective 1,3‐Dipolar Cycloaddition of Carbonyl Ylides DM Hodgson, PA Stupple, FYTM Pierard, AH Labande, C Johnstone Chemistry–A European Journal 7 (20), 4465-4476, 2001 | 130 | 2001 |
| HBO1 is required for the maintenance of leukaemia stem cells L MacPherson, J Anokye, MM Yeung, EYN Lam, YC Chan, CF Weng, ... Nature 577 (7789), 266-270, 2020 | 127 | 2020 |
| Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate CE Mowbray, C Burt, R Corbau, S Gayton, M Hawes, M Perros, I Tran, ... Bioorganic & medicinal chemistry letters 19 (20), 5857-5860, 2009 | 118 | 2009 |
| Catalytic enantioselective tandem carbonyl ylide formation-cycloaddition DM Hodgson, PA Stupple, C Johnstone Tetrahedron letters 38 (36), 6471-6472, 1997 | 112 | 1997 |
| Organocatalytic diastereo-and enantioselective Michael addition reactions of 5-aryl-1, 3-dioxolan-4-ones PS Hynes, D Stranges, PA Stupple, A Guarna, DJ Dixon Organic letters 9 (11), 2107-2110, 2007 | 90 | 2007 |
| Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma S AbuHammad, C Cullinane, C Martin, Z Bacolas, T Ward, H Chen, ... Proceedings of the National Academy of Sciences 116 (36), 17990-18000, 2019 | 88 | 2019 |
| Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and … NA Swain, D Batchelor, S Beaudoin, BM Bechle, PA Bradley, AD Brown, ... Journal of Medicinal Chemistry 60 (16), 7029-7042, 2017 | 76 | 2017 |
| The discovery of a potent, selective, and peripherally restricted pan-Trk inhibitor (PF-06273340) for the treatment of pain SE Skerratt, M Andrews, SK Bagal, J Bilsland, D Brown, PJ Bungay, ... Journal of Medicinal Chemistry 59 (22), 10084-10099, 2016 | 75 | 2016 |
| Sulfonamide derivatives S Beaudoin, MC Laufersweiler, CJ Markworth, BE Marron, DS Millan, ... US Patent 8,153,814, 2012 | 49 | 2012 |
| Sulfonamide derivatives S Beaudoin, MC Laufersweiler, CJ Markworth, BE Marron, DS Millan, ... US Patent 8,153,814, 2012 | 48 | 2012 |
| An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1 S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4, 5, 6, 7 … PA Stupple, DV Batchelor, M Corless, PK Dorr, D Ellis, DR Fenwick, ... Journal of medicinal chemistry 54 (1), 67-77, 2011 | 48 | 2011 |
| Efficient Rh II binaphthol phosphate catalysts for enantioselective intramolecular tandem carbonyl ylide formation–cycloaddition of α-diazo-β-keto esters DM Hodgson, PA Stupple, C Johnstone Chemical Communications, 2185-2186, 1999 | 47 | 1999 |
| Chemical compounds AD Brown, MJ De Groot, BE Marron, DJ Rawson, T Ryckmans, RI Storer, ... US Patent 8,772,293, 2014 | 39 | 2014 |
| Chemical compounds AS Bell, AD Brown, RA Lewthwaite, IR Marsh, DS Millan, MP Pacheco, ... US Patent 8,685,977, 2014 | 38 | 2014 |
| Pyrazole NNRTIs 1: Design and initial optimisation of a novel template CE Mowbray, C Burt, R Corbau, M Perros, I Tran, PA Stupple, R Webster, ... Bioorganic & medicinal chemistry letters 19 (19), 5599-5602, 2009 | 34 | 2009 |
| Full efficacy with no CNS side-effects: unachievable panacea or reality? DMPK considerations in design of drugs with limited brain penetration S Cole, S Bagal, A El-Kattan, K Fenner, T Hay, S Kempshall, G Lunn, ... Xenobiotica 42 (1), 11-27, 2012 | 32 | 2012 |
